Shepherd Ventures III portfolio company AmplifiDX Secures Added Non-Dilutive Funding
NIH funds to AmplifiDX now total $5.7 million to develop technology to diagnose infections at the Point-of-Care and determine drug resistance quickly AUSTIN, TX, UNITED STATES, April 15, 2026 /EINPresswire.com/ -- AmplifiDx, a Shepherd Ventures …